Real-world data on patients with early breast cancer who were prescribed abemaciclib adjuvant therapy in Japan.
Tatsunori ShimoiSwathi PathadkaNobuyuki SekineZhihong CaiYoshinori TanizawaTsutomu KawaguchiShigehira SajiToshinari YamashitaPublished in: Future oncology (London, England) (2024)
Aim: To understand the real-world use of abemaciclib in Japanese patients with early breast cancer (EBC). Methods: This retrospective observational study was conducted using a Japanese administrative claims database in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative EBC who received abemaciclib adjuvant therapy from December 2021-March 2023. Patient characteristics and treatment patterns were summarized. Results: Among 374 patients, 38.2, 51.6 and 63.4% patients received neoadjuvant chemotherapy, adjuvant chemotherapy and radiotherapy, respectively; 13.1% were chemotherapy naive. Tamoxifen (37.7%), letrozole (35.6%), anastrozole (24.3%) were the commonly prescribed concomitant adjuvant endocrine therapies. Abemaciclib dose reductions were observed in 42.0% patients. Conclusion: Use of abemaciclib for treatment of high-risk EBC was described, which could help inform patient selection and treatment patterns.
Keyphrases
- early breast cancer
- neoadjuvant chemotherapy
- epidermal growth factor receptor
- end stage renal disease
- locally advanced
- newly diagnosed
- early stage
- peritoneal dialysis
- type diabetes
- endothelial cells
- radiation therapy
- squamous cell carcinoma
- emergency department
- case report
- adipose tissue
- radiation induced
- lymph node
- electronic health record
- health insurance
- combination therapy
- big data
- skeletal muscle
- polycystic ovary syndrome
- breast cancer cells
- data analysis
- deep learning